Therapeutic Considerations for Docetaxel and Paclitaxel in Metastatic Breast Cancer by Harshini, Doranala et al.
Harshini et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2020; 10(1-s):196-204 
ISSN: 2250-1177                                                                                  [196]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.02.2020 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits 
unrestricted non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                               Review Article  
Therapeutic Considerations for Docetaxel and Paclitaxel in Metastatic 
Breast Cancer 
Doranala Harshini1*, Sreenivas Pasula 2*, Vesangi Keerthi Vaishnavi1, Tekula Shiva Sai1, M. Rajendar3, A. 
Srinivas Rao3, A.V. Kishore Babu1  
1. Pharm D Department of Pharmacy Practice, Bhaskar Pharmacy College, Moinabad, Hyderabad, India 
2 Assistant Professor, Department of Pharmacy  Practice,  Bhaskar Pharmacy  College,  Moinabad,  Hyderabad,  India 
3. Department of Pharmacology Bhaskar Pharmacy College, Moinabad, Hyderabad,  India 
 
ABSTRACT  
Breast cancer is the main source of death among women. Currently, 77% of women diagnosed with breast cancer are age 50 and older; 
however, it is projected that approximately 66% of the new cases diagnosed will occur in women younger than 65. Taxanes are o ne of the most 
effective class of drugs among all the chemotherapeutic agents. They are crucial in the adjuvant therapy of lymph node fantastic or high 
risk/lymph node poor breast cancer. Several clinical trials have assessed the wellbeing and adequacy of taxanes along with their tolerability in 
patients with metastatic cancer (MBC) The overview of these Paclitaxel and Docetaxel, the mechanism of action, pharmacokinetics and 
pharmacodynamics, dose and administration, adverse effects, clinical potency, and sufferable profiles combination therapies, the pathological 
complete response of these taxanes are included. The different novel formulations of taxanes are formulated from nanoparticles, polyglutamate, 
liposomes to improve the wellbeing and adequacy taxanes to reduce their toxicities. Single-agent research located with docetaxel and paclitaxel 
in metastatic breast most cancers show clinically huge antitumor motion even in the advanced stage, heavily pretreated, safe,  as properly as in 
refractory diseases. This action is likewise clear with taxane-based combination regimens. Serious hematologic and nonhematologic toxicities 
are incompatible, with different toxicities noted dependent on the portion and weekly regimen selected.  Weekly docetaxel and paclitaxel 
regimens speak to important helpful treatment options for women suffering from metastatic breast cancer and have entered assessment as a 
major aspect of adjuvant treatment for this disease Toxicity associated with taxanes chemotherapy are based totally on the do se schedules and 
weekly regimen selected and the most frequent toxicities related with these marketers include myalgia, peripheral neuropathy, neutropenia, 
etc Docetaxel retains in tumor cells for longer duration when compared to paclitaxel because of its slow efflux and large amounts of uptake into 
the cell which explains its more benefits when compared to paclitaxel. Clinical studies conducted so far suggested a more benefit to risk ratio 
for docetaxel when compared to paclitaxel. This article reviews mainly different actions exhibited by taxanes in the therapy of metastatic breast 
cancer and others on stages of cancer along with the toxicities associated with these agents.  
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INTRODUCTION:  
Worldwide, breast cancer is leading cancer in females. 
Neoadjuvant chemotherapy administered before medical 
surgery is the possible treatment option for various breast 
cancer patients [1]. Preoperative chemotherapy diminishes 
the primary tumor thereby facilitating breast conservation 
[2, 3].  
Preoperative chemotherapy administration on open 
tumors before the medical procedure likewise gives the 
chance to quickly measure tumor reaction and identify the 
patients who responded to the therapy. It also helps in 
attaining pathological complete response (pCR) which is 
often described by the destruction of all malignant cells 
from the breast and also from axillary lymph nodes, which 
is the primary endpoint for disease-free tolerance after 
neoadjuvant therapy, particularly in triple-negative breast 
tumor [4, 5].  
Clinical parameters, for example, estrogen receptor-
negative status, excessive histological evaluation, and high 
proliferative fame are associated with excessive 
affectability to chemotherapy [5, 6]. Of all the new anti-
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cancer agents developed, the taxanes had a significant 
effect on wide varieties of malignancies. Paclitaxel 
(“Figure.1”) and docetaxel(“Figure.2”)  
 
Paclitaxel(figure:1) 
Docetaxel(figure: 2) 
are treatment options for clinical use approved by the food 
and drug administration (FDA) board for the therapy of 
breast malignancy, ovarian disease, non-small cell lung 
cancer (NSCLC) and prostate cancer growth.  
The taxanes are a special type of hydrophobic 
antineoplastic seller that shows cytotoxic action by way of 
binding to tubulin and promoting inappropriately stable, 
non-functional microtubule arrangement [7]. Disruption of 
the microtubule arrangement leads to telephone death. 
The toxicity profiles for these retailers are pretty 
extraordinary; Paclitaxel has adverse effects like 
peripheral neuropathies and myalgias/arthralgias, though 
docetaxel most usually associated with fluid retention that 
might be dose-limiting at some cases [8].  
Docetaxel has been known to cause infusion-related 
responses such as hypersensitivity reactions without 
premedication; in any case, these responses have 
happened at a decreased frequency when compared with 
paclitaxel and can be successfully overseen by 
premedication with corticosteroids and histamine receptor 
antagonist [9]. A few procedures are in progress to create 
alternative formulations of paclitaxel and docetaxel, 
including the utilization of albumin, nanoparticles, 
prodrugs, polyglutamate, analogs, emulsions, and 
liposome, in order to minimize the vehicle-related 
unfavorable impacts, overcome resistance related to P-
glycoprotein and the multi-drug resistant (MDR )gene, and 
increase reaction rates compared to accomplished with the 
standard taxanes therapy[10]. 
 
 
Table 1. Drug characteristics of novel taxane formulations 
Compound Formulation 
vehicle  
% parent 
compound 
Administration 
time 
Pre medications 
required? 
P- glycoprotein substrate 
Paclitaxel 
Docetaxel 
Nab paclitaxel 
DHA-paclitaxel 
Paclitaxel poly glumex 
BMS- 184476 
 
DJ-927 
 
 
BMS-275183 
 
 
Cremophor EL 
Polysorbate 80 
- 
Cremophor EL 
- 
Cremophor EL 
 
- 
 
 
- 
100% 
100% 
10% 
73% 
37% 
- 
 
- 
 
 
- 
i.v over 1,3or 24hr 
i.v over 1hr 
i.v over 30min 
i.v over 2hrs 
i.v over 10mins 
i.v over 1hr 
 
oral( single dose) 
 
 
Oral (single dose) 
Yes 
Yes 
No  
Yes 
No 
Further evaluation 
warranted 
No 
 
 
No 
Yes 
Yes 
No data available 
Yes 
yes 
Moderate 
 
Poor 
 
 
Poor 
Ortataxel - - Oral daily for 5 
days  
No Poor 
      
RPR 109881A 
 
Polymeric-miscellar 
paclitaxel 
Polysorbate 80 
 
Polymeric micelles 
- 
 
25% 
i.v ranging from 1-
24hr 
i.v over 3hrs 
Yes 
 
No 
Poor 
 
Yes 
      
Paclitaxel injectable 
depot 
Liposomal 
encapsulated paclitaxel 
ReGel delivery 
system 
 
- 
100% 
 
 
Data 
unavailable 
Intratumoral 
delivery 
 
i.v over 45mins 
No 
 
 
Further evaluation 
warranted 
- 
 
 
Yes 
      
Paclitaxel vitamin E 
emulsion 
- 100% i.v over 15mins No Formulation contains P-
glycoprotein inhibitors 
Microsphere 
encapsulation of 
paclitaxel 
PACLIMER 
delivery system 
10% or 40% Intratumoral 
delivery 
No - 
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Molecular pharmacology:  
Docetaxel and paclitaxel are diverse in their molecular 
pharmacology, conceivably clarifying their different 
activity and toxicity profiles (table 2) 
.  
Table 2: mechanistic difference between docetaxel and paclitaxel [44,45,46] . 
Property Docetaxel Paclitaxel Comments 
High-affinity β tubulin-binding 1.9 1.0 Higher intracellular drug concentrations are associated with 
higher log cell kills and inhibition of tumor growth 
Drug concentration causing 
maximum polymerization 
0.2µM 0.4µM Docetaxel is as twice potent as paclitaxel in inhibiting microtubule 
depolymerization.  
Microtubule target  
 
 
Cell cycle specificity(phase) 
centrosome 
organisation 
 
S,G2,M 
mitotic spindle 
 
 
G2, M 
Docetaxel affects centrosome organization in the S-phase resulting 
in incomplete mitosis and cell death; It is only partially toxic 
against cells in the mitosis and has minimal toxicity against cells in 
G1, leading to an accumulation of cells in the G2/M phase; This 
differs from paclitaxel, which causes cell damage by affecting the 
mitotic spindle. 
    
 
Docetaxel shows a greater affinity to ß-tubulin, focusing on 
centrosome organization and shows its effects three 
different stages of cell cycle (S/G2/M), while paclitaxel 
causes cell damage by disrupting the mitotic spindle in the 
G2 and M stages of cycle [ 44]. Docetaxel is a cell cycle-
specific targeted therapy which acts on S-phase, while the 
most extreme resistance to S-phase is found with paclitaxel 
[45].  
An additional difference between the taxanes incorporates 
greater take-up of docetaxel into tumor cells and more 
slow efflux of docetaxel from tumor cells, accordingly 
prompting longer maintenance times, giving a potential 
clarification to the inadequate cross-resistance between 
the drugs [46]. 
 
PHARMACOKINETICS AND PHARMACODYNAMICS:  
There are generous differences in the pharmacokinetic and 
pharmacodynamic profiles of docetaxel and paclitaxel, an 
issue that may add to the troubles is with characterizing 
the ideal plan for paclitaxel monotherapy and combination 
regimens, especially with anthracyclines.  
Both taxanes are broadly metabolized in the liver by the 
cytochrome P-450 compounds and experience biliary 
excretion as their primary source of elimination, in this 
way bringing about the requirement for dose reductions in 
patients with raised liver enzymes. A significant division of 
the taxane portion is discharged in feces as parent drug or 
hydroxylated metabolites; the familiar metabolites of both 
taxanes are either inert or less intense than the parent 
compound. The both taxanes have broadly distribution of 
tissue, profoundly protein-bound, and roughly 6% of either 
medication are renally eliminated [47].  
 
 
 
Weekly Docetaxel administration in MBC 
Weekly Single-Agent Docetaxel  
Weekly Docetaxel administration in MBC Weekly Single-
Agent Docetaxel Weekly management of docetaxel has 
been assessed in phase II trials of women with MBC (Table 
3) [11-23]. the bulk of patients in those examinations had 
arranged earlier chemotherapy for MBC and most had an 
Eastern Cooperative Oncology Group (ECOG) performance 
status score of 0 or 1. 
Stemmler et al. [34] detailed median times to progression 
(TTPs) of 6.6 months in chemotherapy-credulous patients 
and 5.9 months in pretreated patients; in like manner, 
Aihara et al. [20] and Kim et al. [12] announced a median TTP 
of 5 months. In patients resistant to anthracyclines, Ramos 
et al. [14] announced 8.4  
months as the median time to illness progression. The 
medial overall endurance in these trails went from 13–14 
months [14, 19-21]. Weekly docetaxel regimens were very 
much tolerated, and grade 4 toxicities were uncommon. 
The most well-known 3 toxicities associated with 
docetaxel include neutropenia, frailty, and 
fatigue/asthenia; Ocular toxicity is generally presented as 
increased lacrimation. This increased lacrimation is due to 
canalicular stenosis [22] and also nail toxicities were 
likewise prominent. Stemmler et al. randomized patients to 
get either dexamethasone (Decadron®; Merck and Co., 
Inc., Whitehouse Station, NJ, http://www.merck.com) 
premedication or no premedication; patients who got 
dexamethasone had a fundamentally lower frequency of 
nail changes these investigations show that week by week 
docetaxel administration l at portions of 35–40 mg/m2 has 
clinical action in MBC, creating reactions in 30%–40% of 
pretreated patients, with a median TTP of around 7 
months. This schedule is related with a low rate of the 
classic grade 3–4 hematologic and nonhematologic 
toxicities reported with every 3-week regular intervals 
plans.
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Table 3: Chosen stage II investigations of weekly single-agent docetaxel in metastatic breast cancer (MBC) 
Study  Patient 
characters (% 
of subjects) 
Treatment 
regimen 
No.of 
evaluable 
patients 
       ORR(CR) Grade ≥3 toxicity in ≥5% of 
patients(% of patients) 
Burstein et 
al[18]. 
Previously 
treated MBC 
(66%); ECOG 
PS score 0–1 
(97%); ER 
positive 
(65%); ≥3 
metastatic 
sites (65%) 
 
Docetaxel, 40 
mg/m2 i.v. 
weekly × 6 
weeks follow 
by 2-week rest 
29 41% (0) Neutropenia (14%), fatigue/ asthenia 
(14%) 
Stemmler et al. 
[19] 
Previously 
treated MBC 
(85%); ECOG 
PS score ≤2 
Docetaxel, 35 
mg/m2 i.v. 
weekly × 6 
weeks follow 
by 2-week rest; 
then 
docetaxel,35 
mg/m2 i.v. 
weekly × 3 
weeks follow 
by 2-week rest 
100 42% (10%) Neutropenia (1% of cycles), anemia (6% 
of cycles), alopecia (25%), asthenia 
(6%), pain (7%) 
      
Aihara et al. [20] 
 
 
 
 
 
 
 
 
Hainsworth et 
al. [21] 
 
 
 
 
 
 
 
Estevez et al. 
[22] 
 
 
 
 
 
 
Previously 
treated MBC 
(25%); median 
age, 74 years 
(range, 50–
88); ECOG PS 
score 0–1 
(78%); ER -
positive (56%) 
 
Previously 
treated MBC 
(25%); median 
age, 74 years 
(range, 50–
88); ECOG PS 
score 0–1 
(78%); ER -
positive (56%) 
 
formerly 
untreated 
LABC; median 
age, 53 years 
(range, 28–
73); ECOG PS 
score 0 (98%); 
stage II, 87%; 
stage III 13% 
 
seriously 
pretreated 
MBC; weak or 
elderly 
patients (over 
70 years of 
age); norm age, 
Docetaxel,40 
mg/m2 i.v. 
weekly × 3 
weeks; cycles 
repeated every 
4 weeks 
 
 
 
Docetaxel,36 
mg/m2 i.v. 
weekly × 6 
weeks, 
followed by 2-
week rest 
 
 
 
 
Docetaxel,40 
mg/m2 i.v. 
weekly for the 
first 6 weeks of 
an 8-week 
cycle for 2 
cycle 
 
 
 
 
Docetaxel,36 
mg/m2 once 
weekly for the 
37 
 
 
 
 
 
 
 
36 
 
 
 
 
 
 
 
 
 
56 
 
 
 
 
 
 
 
38%(0) 
 
 
 
 
 
 
 
36%(3%) 
 
 
 
 
 
 
 
 
 
68%(16%pCR 
rate) 
 
 
 
 
 
 
Neutropenia (19%) 
 
 
 
 
 
 
 
Leukopenia (5%), anemia (5%), 
fatigue/asthenia (20%), diarrhea (10%), 
nausea/vomiting (7%), peripheral 
edema (7%) 
 
 
 
 
 
 
 Neutropenia, asthenia (16%), nail 
disorders (16%), cutaneous toxicity 
(14%) 
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D’Hondt et al.   
[23] 
 
 
 
 
 
 
 
 
 
 
 
 
Ford et al. [13] 
 
 
 
 
 
 
 
Ramos et al. 
[14] 
 
 
 
 
 
 
 
 
 
Kim et al. [12] 
 
 
 
Jackisch et al. 
[11] 
 
63 years 
(range, 43–
82); ECOG PS 
score 1 (34%), 
2 (55%), and 3 
(9%); ER-
positive, 62 
 
Anthracycline 
expose 
MBC:Second 
line 
management 
(54%)norm 
age 53 
years(34-74) 
 
Anthracycline 
-resistant 
LABC/MBC 
 
 
 
 
 
 
 
 
Pretreated 
recurring 
breast cancer; 
Japanese 
patients 
 
Pretreated 
MBC (100%); 
second-line 
treatment 
(98.1%); norm 
age 58 years 
(range, 31–
80); Karnofsky 
performance 
status 60%–
100% 
initial 6 weeks, 
follow by 1-
week rest 
 
 
 
 
 
 
 
 
Docetaxel,35 
mg/m2 once 
weekly × 6 
weeks, follow 
by 2-week rest 
 
 
 
Docetaxel,40 
mg/m2 for 6 
successive 
weeks, follow 
by 2-week rest 
in first 18 
patients; 
reduced to 36 
mg/m2 for the 
next 17 patient. 
 
Docetaxel,40 
mg/m2 once 
weekly × 3 
weeks, follow 
by 1-week rest 
 
Weekly 
docetaxel, 35–
40 mg/m2 
 
 
 
 
 
 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
 
 
 
 
 
35 
 
 
 
 
 
 
 
 
 
 
36 
 
 
60 
 
 
30%(0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
29%(NR) 
 
 
 
 
 
 
 
34%(6%) 
 
 
 
 
 
 
 
 
 
 
39%(3.4%) 
 
 
33.4%(6.7%) 
 
 
Neutropenia(22%), thrombocytopenia 
(6%), 
 
 
 
 
 
 
 
 
 
 
 
 
Fatigue(16%) 
 stomatitis 7%, diarrhea 14%, cutaneous 
toxicity 19 
 
 
 
 
 
neutropenia(17%),asthenia, nail, visual, 
and cutaneous disorders 
 
 
 
 
 
 
 
 
 
Neutropenia(16.2%) 
dysgeusia (18.9%), dacryorrhea 
(16.2%), acoustic disturbance (16.2% 
 
neutropenia(3.5%) 
alopecia(14.3%) 
 
 
 
Abbreviations: CR- complete response; ECOG- Eastern Cooperative Oncology Group; ER-estrogen receptor; LABC-locally 
advanced breast cancer; NR- not reported; ORR- overall response rate; pCR- pathologic complete response; PS- performance 
status. 
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Weekly Docetaxel-Based Combination Regimens 
in MBC  
The promising results of studies studies assessing weekly 
docetaxel because every single agent gives the basis for 
evaluating weekly docetaxel in combination chemotherapy 
regimens for MBC. phase I and stage II trials have 
evaluated weekly docetaxel regimens combination with 
anthracyclines [24-27], gemcitabine [28-32], vinorelbine [29, 33], 
and trastuzumab [34]      
The combination of two inhibitors of microtubule function, 
docetaxel, and estramustine demonstrated to be too toxic 
to even think about being researched further [35]. These 
investigations demonstrate that weekly docetaxel    in 
combination with anthracycline, gemcitabine, or 
vinorelbine is achievable. The activity in both recently 
treat and untreated patients    ith MBC is great (up to 85%–
90% in untreated patients [24, 25].  
However, this degree of activity is accomplished at the 
expense of higher lethality, with higher rates of 
neutropenia, febrile neutropenia, asthenia, and alopecia. 
These combination regimens may comprise a possibility 
for young, fit patients giving an extensive, hazardous 
disease, for whom a quick and significant tumor volume 
decrease is required. 
 Docetaxel–Trastuzumab Combinations 
 Docetaxel–trastuzumab combination is incredibly 
dynamic when utilized as a weekly treatment in HER-2–
positive patients, with reaction rates in the range of 55%–
75%, even in pretreated patients.  
The toxicity quality profile is entirely good, with the 
evaluation of grade 3–4 toxicities, supporting the 
utilization of this regimen as a forefront treatment for this 
patient population [43].  
Week by week Paclitaxel in MBC  
Weekly Single-Agent Paclitaxel 
 Like docetaxel, paclitaxel given on a weekly plan has been 
considered broadly both being a single agent also in blend 
chemotherapy. Common toxicities related to the regular 
intervals of paclitaxel dosing are neutropenia, neuropathy, 
and arthralgia/myalgia. Week by week dosing of paclitaxel 
has been evaluated as a way to improve dose quantity and 
enhance tolerability.A several phases II studies have 
assessed weekly paclitaxel dosing as a single-agent 
treatment in subjects with MBC (Table 4). 
 Seidman and partners assessed constant paclitaxel 
treatment, 100 mg/m2 every week, in 30 women with MBC 
who had gotten earlier adjuvant or potentially metastatic 
treatment (Table 3) [36]. Three patients in that review 
accomplished complete response (10%) and 16 
accomplished partial response (43%) for an ORR of 53% 
(95% CI, 34%–72%). Treatment was commonly very much 
tolerated.  
 
Evaluation 3–4 neutropenia happened in four patients, 
without any episodes of febrile neutropenia. There was no 
proof of cumulative neutropenia and no cases of 
thrombocytopenia. The main incessant evaluation 3 
nonhematologic harmfulness was neurosensory toxicity in 
seven patients (24%), five of whom had gotten paclitaxel 
dosages of 110–120 mg/m2 [36]. A phase II analysis gave a 
statement of the utilization of weekly paclitaxel (100 
mg/m2) administrated as first-line chemotherapy for MBC 
[37]. 
 
 
Table 4. chosen phase II/III study of weekly single-agent paclitaxel during metastatic breast cancer (MBC) 
Study/phase Patient 
characteristics(% of 
patients) 
Treatment 
regimens 
No. of 
evaluab
le 
patients  
ORR(CR) Grade ≥3 toxicity in ≥5% of 
patients (% of patients 
Seidman[37] Previously treated 
(43%) and untreated 
(57%) MBC; median 
age, 57 years (range, 
35–74); median KPS, 
90 (range, 70–100); ≥3 
metastatic sites (24%) 
Paclitaxel, 100 
mg/m2 i.v. 
weekly until 
development 
 
30 53%(10%) Leukopenia (17%), 
neutropenia (14%), 
neurosensory (24%), 
hyperglycemia (7%) 
      
Wist et al. [37] 
Phase II 
Previously untreated 
MBC; norm age, 53 
(range, 33–68); prior 
adjuvant CT (60%); no 
Prior CT for MBC; ≥2 
metastatic site (49%) 
Paclitaxel, 100 
mg/m2 i.v. 
weekly until 
development 
33 40%(3%) Neutropenia (14%), 
neurotoxicity (14%) 
 
      
Akerley et al[39]. 
Phase II 
Previously untreated 
MBC or unresectable 
LABC; median age, 58 
years 
Paclitaxel, 175 
mg/m2 i.v. 
weekly × 6 
weeks followed 
by  2-week 
break; cycles 
recurring until 
MBC: 18 
LABC: 
14 
78% (11%) 78% 
(21% 
Neutropenia(65%)grade 
2–3 myalgia (25%), grade 2–3 
hyperglycemia (19%), grade 
2–3 rash (16%), grade 2–3 
mucositis (16%), grade 2–3 
nausea (13%), grade 2–3 
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PD diarrhea (13%) 
      
Perez et al. [40] 
Phase II 
Previously treated 
(69%) and untreated 
(31%) MBC; mean age, 
60 years (range, 31–
88); ECOG PS score 0–1 
(88%); ≥3 metastatic 
sites (46%); prior 
anthracyclines (72%); 
former taxanes (25%) 
Paclitaxel, 80 
mg/m2 i.v. 
weekly × 4 
weeks; cycles 
repeated until 
PD or excessive 
toxicity 
177 22% 
(2%) 
Neutropenia(15%),anemia(9
%), neuropathy (9%) 
 
      
ten Tije et al.[41] 
Phase II 
 
 
 
 
Hormone-refractory 
elderly (>70 years) 
MBC; median age, 77 
(range, 71–84); prior 
adjuvant CT (5%); no 
Prior CT for MBC; ≥3 
metastatic sites (50%) 
Paclitaxel, 80 
mg/m2 
administer 
weekly on days 
1, 8, and 15 of a 
28-day cycle 
23 38% 
(0%) 
Neutropenia(12%), 
anemia(12%), neuropathy 
(4% 
Sikov et al. [42] 
Phase III 
 
 
 
 
Lombardi et al. 
[38] 
MBC; norm age, 57 
years (range, 30–86); 
prior adjuvant CT 
(57%); prior CT for 
MBC (14%) 
 
 
Previously treated 
MBC; anthracycline 
contact (90%); norm 
age, 54 years(range, 
38–72) 
 
 
 
 
Paclitaxel, 150 
mg/m2 i.v. 
weekly × 6 
weeks followed 
by 2-week rest; 
cycles repetitive 
every 8 weeks × 
2 
Paclitaxel,150 
mg/m2i.v. 
weekly × 2 
weeks followed 
by 1-week rest; 
cycles repetitive 
every 3 weeks × 
5 
 
Paclitaxel 80 
mg/m2 weekly 
× 15 weeks 
 
Paclitaxel, 90 
mg/m2 i.v. 
weekly 
72 
 
 
 
 
 
70 
 
 
 
 
 
74 
 
 
58 
50%(NR) 
 
 
 
 
 
50%(NR) 
 
 
 
 
 
42%(NR) 
 
 
48%(8%) 
Neutropenia(67%),febrile 
neutropenia (8%), anemia 
(6%), neuropathy (17%), 
diarrhea (5%) 
 
 
 
Neutropenia(69%), febrile 
neutropenia (14%), anemia 
(7%), neuropathy (21%), 
diarrhea (19%) 
 
 
 
Neutropenia(18%),anemia(8
%), neuropathy (7%) 
 
 
Neutropenia(15%) 
ªPaclitaxel doses could be increased or decreased at 10-mg/m2 increment after 4 weeks, then every 2 weeks.  
Abbreviations: CR-complete response; CT- chemotherapy; ECOG- Eastern Cooperative Oncology Group; KPS,-Karnofsky 
performance status; LABC- locally advanced breast cancer; NR- not reported; ORR- overall response rate; PD- progressive 
disease; PS- performance status 
 
Weekly Paclitaxel-Based Combination Regimens 
in MBC: 
Evaluating weekly paclitaxel in MBC present the basis for 
evaluating the therapy method for combination regimens. 
Weekly paclitaxel has been examined in combination with 
anthracyclines, platinum specialists, and trastuzumab.  
collectively, these examinations demonstrated that 
paclitaxel in blending by anthracyclines or platinum can 
accomplish reaction rates from 42% up to 82%, with a 
median TTP of a while. The most regular evaluation 3–4 
toxicities recorded were neutropenia, alopecia, and 
neuropathy. These underlying phase I/II think about 
demonstrated the attainability of the various schedules to 
be additionally assessed in randomized stage III trails. 
Weekly Paclitaxel–Trastuzumab Combinations. 
Paclitaxel in sequence with trastuzumab is highly active 
regimen that can shorten neoplasms in 56%–86% of the 
HER-2–positive breast cancer patients, beside a low 
frequency of evaluation 3–4 toxicities. It gives a reliable 
and efficient treatment that can give 8-12months 
progression-free durability for the subgroup of patients 
overexpressing HER-2[43]. 
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TOXICITIES OF THE TAXANES 
The different taxanes are likewise clear in their 
antagonistic impact profiles. Paclitaxel is related to 
anaphylaxis and severe hypersensitivity responses 
followed by hypotension, dyspnea, angioedema, and 
generalized urticaria. Different replies normally more 
recognized by paclitaxel than docetaxel include myalgias 
and neuropathy. Every symptom profile of docetaxel gives 
off the impression of being scheduled dependent.  
When given at regular intervals, docetaxel is all the more 
as often as possible related to reversible, noncumulative 
neutropenia, fluid retention, cutaneous responses, and 
hyperlacrimation (Table 3). Be that as it may, when 
directed utilizing a week by week dosing plan, the toxicity 
profile of docetaxel is extraordinary and incorporates less 
hematologic toxicities, less stomatitis, less cutaneous 
occasions, and less neurologic toxicities, however a more 
noteworthy measure of evaluation 3/4 
exhaustion/asthenia [48]. Reactions regular to the both 
methods for administration include hyperlacrimation and 
fluid retention. Reactions regular to the both methods for 
administration include hyperlacrimation and fluid 
retention. Less acute toxicity has associated with related to 
weekly docetaxel treatment than with each 3-week 
docetaxel treatment. 
 
Table 5: management of Docetaxel-specific toxicities [48]. 
ADVERSE REACTION MANAGEMENT 
Fluid retention : weight gain and peripheral edema compared 
to total dose(5th-7th cycle) 
2-3 days of steroid treatment responding to diuretics. 
Skin and nail disorders 
Palmar- Plantar erythrodysesthesia 
Onycholysis and soreness(rare) 
 
Healthy skin and nail care. 
Cyclo oxygenase-2- inhibitor under study. 
Hyperlacrimation(epiphora) 
Primarily associated with weekly schedule and cumulative 
dose above 300mg/m2 
Instillation of artificial tears. 
Lacrimal canicular prosthesis. 
 
Which Is the Preferred Taxane? 
In view of indirect correlations just as the results of the 
ongoing randomized trials led in patients with MBC, 
docetaxel by all accounts seems to be the more active taxane 
. In addition to its more extended half-life, docetaxel has an 
increasingly quick cell take-up and longer intracellular 
retention than paclitaxel [48]. Due to its pharmacokinetics, the 
adequacy of paclitaxel is schedule dependent. In general, 
patterns of predominant reaction rates have been related 
with higher dosages and delayed infusion rates, yet no 
routine of paclitaxel has been proved to be measurably 
better than some other in MBC. Docetaxel is particularly 
active when given as a short, periodic infusion. 
Conclusion: 
The epic details of taxanes do hold some guarantee in 
disease treatment and may give humble improvement in 
results. Clearly, there are contrasts between the taxanes, 
extending from their binding affinity and cell cycle-specific 
nature to their lethality profiles.  Generally the difference in 
the   correlation between agents is uncommon and hard to 
achieve. 
At the present time, clinicians must to pick a taxane-based 
routine for their patients with breast cancer dependent on 
the consideration of the pharmacokinetics, clinical activity, 
and dosing schedule that best addresses the patient's issues. 
Keeping that in mind, the pharmacokinetic profile, 
predictable positive clinical outcomes, and convenience of 
the intermittent, short-infusion schedule support the 
utilization of docetaxel for some patients with breast cancer 
at this time.Overall, several adverse effects remained seen 
with docetaxel than with some of the paclitaxel schedules for 
particular neutropenia, weakness, and peripheral 
neuropathy. 
Optimizing the dose and schedule of taxane therapy to 
increase antitumor action while keeping up a safe toxicity 
profile stays an important objective in metastatic breast 
cancer (MBC). Weekly, instead of the measure every 3 
weeks, dosing regarding docetaxel and paclitaxel at more 
moderate portions is one approach to give an effective 
method of drug delivery while managing a favorable toxicity 
characterization 
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